Copyright: ©Author(s) 2026.
World J Gastrointest Surg. Jun 27, 2026; 18(6): 119272
Published online Jun 27, 2026. doi: 10.4240/wjgs.119272
Published online Jun 27, 2026. doi: 10.4240/wjgs.119272
Figure 2 Adjuvant therapy regimen details.
Cam: Camrelizumab; Pem: Pembrolizumab; Tis: Tislelizumab; Tor: Toripalimab; Anl: Anlotinib; Apa: Apatinib; Len: Lenvatinib; Sor: Sorafenib.
- Citation: Li QS, Hu AY, Chen SJ, Yu GJ, Fan Y, Chen YG, Tian S, Peng CJ, Han M. Efficacy and safety of adjuvant targeted immunotherapy for hepatocellular carcinoma with high recurrence risks after hepatectomy. World J Gastrointest Surg 2026; 18(6): 119272
- URL: https://www.wjgnet.com/1948-9366/full/v18/i6/119272.htm
- DOI: https://dx.doi.org/10.4240/wjgs.119272